Jackson Walker successfully represented its client Repros Therapeutics Inc. (Nasdaq: RPRX) in the offering of $23.6 million in unregistered shares of common stock.
On August 28, 2012, Repros Therapeutics entered into a purchase agreement with several institutional investors and shareholders to sell approximately 2.15 million shares of common stock at $11 per share. Closing occurred on September 7, 2012. The Woodlands, Texas-based biopharmaceutical company will use the proceeds to fund development for its Androxal and Proellex drug programs. A registration statement registering the resale of the shares sold in the private placement was filed with the U.S. Securities and Exchange Commission on September 28.
A Jackson Walker team led by Jeff Harder, with assistance from Steve Jacobs, Marisela M. Peña and Joseph Fonlon, represented Repros Therapeutics in the transaction. Attorneys in Jackson Walker’s Corporate & Securities practice group have extensive experience representing clients in complex corporate matters, including IPOs, PIPEs, proxy contests, tender offers, going-private transactions, mergers and acquisitions, and corporate partner and license transactions. In addition, the firm’s attorneys have an advanced understanding of the unique and sophisticated needs of clients in the Biotech, MedTech and Life Sciences sector.
Related Posts:
- None Found
